Caracterizações bioquímica e hemostática de pacientes com diabetes Mellitus Tipo 2 em insulinização
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) |
Texto Completo: | http://repositorio.ufes.br/handle/10/5137 |
Resumo: | The study aims to characterize biochemically and hemostatic mellitos patients with diabetes mellitus type 2 (DM2) who developed insulin regimen. Composed group under analysis, 40 patients attended the Basic Health Unit of Consolation, Vitória / ES, aged 25 to 80 years, diagnosed with DM2 and that were already evoluted to insulinization. As controls, 40 patients were selected in the same age group without laboratory and / or clinical diagnosis of DM. Markers of inflammation, hypercoagulability and fibrinolysis were measured: Fibrinogen, D-dimer (D-Di) and plasminogen activator type 1 inhibitor (PAI-1). The polymorphism (-675 4G/5G) in the promoter region of the PAI-1 gene was correlated with their serum levels. Biochemical parameters were measured: plasma glucose (PG), glycated hemoglobin (A1C), total cholesterol (TC), HDL cholesterol (HDL-C), LDL (LDLc) cholesterol, triglycerides (TGC), ultrasensitive C reactive protein (hsCRP), urea and serum creatinine. There was still checking BMI, obesity, smoking, hypothyroidism, hypertension, dyslipidemia and insulin resistance. Statistical analysis showed significant differences (p <0.05) between groups with regard to mean values of HDLC, VLDL-C, TGC, urea, hsCRP and fibrinogen. There was significant difference between groups for VLDLc, TGC, creatinine and fibrinogen. Controls present correlations between: fibrinogen and glucose, hsCRP and fibrinogen, PAI-1 and glucose, PAI-1 and BMI. In insulinization DM2 group correlation was observed correlation between: fibrinogen and D-di, hsCRP and fibrinogen, D-Di and glucose (negative), PAI-1 and triglycerides, PAI-1 and BMI. PAI-1 levels were higher in the control group in subjects with genotype 5G5G, 4G5G and 4G4G followed. Binary Logistic Regression confirmed that the variables hypertension and fibrinogen were significant at p-value (0.009) and (0.049) and adjusted odds ratio (4.184, 1.426 to 12.276) and (3.293, 1.006 to 10.775), respectively, showing that hypertensive patients have a risk 4.18 times more likely to have insulinization type 2 diabetes and that individuals with hyperfibrinogenemia have a 3.29 times greater risk. With this study we hope to contribute to better understanding of the complex changes that accompany the user insulinization type 2 diabetic patients in expectation of seeking appropriate treatment and prevention for the macrovascular complications of diabetes. |
id |
UFES_16795797471921a91923e9e51062eca8 |
---|---|
oai_identifier_str |
oai:repositorio.ufes.br:10/5137 |
network_acronym_str |
UFES |
network_name_str |
Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) |
repository_id_str |
2108 |
spelling |
Bem, Daniela Amorim Melgaço Guimarães doGonçalves, Nadmy Arrivabene ZavarisVassalo, Breno ValentimGomes, Isabele Beserra Santos2016-08-29T15:37:45Z2016-07-112016-08-29T15:37:45Z2014-07-15The study aims to characterize biochemically and hemostatic mellitos patients with diabetes mellitus type 2 (DM2) who developed insulin regimen. Composed group under analysis, 40 patients attended the Basic Health Unit of Consolation, Vitória / ES, aged 25 to 80 years, diagnosed with DM2 and that were already evoluted to insulinization. As controls, 40 patients were selected in the same age group without laboratory and / or clinical diagnosis of DM. Markers of inflammation, hypercoagulability and fibrinolysis were measured: Fibrinogen, D-dimer (D-Di) and plasminogen activator type 1 inhibitor (PAI-1). The polymorphism (-675 4G/5G) in the promoter region of the PAI-1 gene was correlated with their serum levels. Biochemical parameters were measured: plasma glucose (PG), glycated hemoglobin (A1C), total cholesterol (TC), HDL cholesterol (HDL-C), LDL (LDLc) cholesterol, triglycerides (TGC), ultrasensitive C reactive protein (hsCRP), urea and serum creatinine. There was still checking BMI, obesity, smoking, hypothyroidism, hypertension, dyslipidemia and insulin resistance. Statistical analysis showed significant differences (p <0.05) between groups with regard to mean values of HDLC, VLDL-C, TGC, urea, hsCRP and fibrinogen. There was significant difference between groups for VLDLc, TGC, creatinine and fibrinogen. Controls present correlations between: fibrinogen and glucose, hsCRP and fibrinogen, PAI-1 and glucose, PAI-1 and BMI. In insulinization DM2 group correlation was observed correlation between: fibrinogen and D-di, hsCRP and fibrinogen, D-Di and glucose (negative), PAI-1 and triglycerides, PAI-1 and BMI. PAI-1 levels were higher in the control group in subjects with genotype 5G5G, 4G5G and 4G4G followed. Binary Logistic Regression confirmed that the variables hypertension and fibrinogen were significant at p-value (0.009) and (0.049) and adjusted odds ratio (4.184, 1.426 to 12.276) and (3.293, 1.006 to 10.775), respectively, showing that hypertensive patients have a risk 4.18 times more likely to have insulinization type 2 diabetes and that individuals with hyperfibrinogenemia have a 3.29 times greater risk. With this study we hope to contribute to better understanding of the complex changes that accompany the user insulinization type 2 diabetic patients in expectation of seeking appropriate treatment and prevention for the macrovascular complications of diabetes.O estudo objetivou caracterizar hemostática e bioquimicamente pacientes com diabetes mellitos tipo 2 (DM2) que evoluíram para insulinização. Compuseram o grupo em análise, 40 pacientes atendidos pela Unidade Básica de Saúde de Consolação, Vitória/ES, com idade entre 25 e 80 anos, diagnóstico de DM2 em utilização de insulina. Para o controle, foram selecionados 40 pacientes na mesma faixa etária, sem diagnóstico laboratorial e/ou clínico de DM. Foram dosados marcadores de inflamação, hipercoagulabilidade e fibrinólise: fibrinogênio, dímero-D (D-Di) e inibidor do ativador do plasminogênio tipo 1 (PAI-1). O polimorfismo (-675 4G/5G) na região promotora do gene do PAI-1 foi correlacionado com seus níveis plasmáticos. Foram medidos os parâmetros bioquímicos: glicemia de jejum (GJ), hemoglobina glicada (HbA1C), colesterol total (CT), colesterol HDL (HDLc), colesterol LDL (LDLc), triglicerídeo (TGC), proteína C reativa ultra sensível (PCRus), ureia e creatinina plasmáticas. Houve ainda a verificação do IMC, obesidade, tabagismo, hipotireoidismo, hipertensão, dislipidemia e resistência à insulina. A análise estatística mostrou diferença (p < 0,05) entre os grupos em relação aos valores médios de HDLc, VLDLc, TGC, ureia, PCRus e fibrinogênio. Houve diferença entre os grupos para VLDLc, TGC, creatinina e fibrinogênio alterados. No controle foram observadas as correlações: fibrinogênio e glicemia, fibrinogênio e PCRus, PAI-1 e glicemia, PAI-1 e IMC. No grupo DM2 em insulinização houve correlação para fibrinogênio e D-di, fibrinogênio e PCRus, D-Di e glicemia (negativa), PAI-1 e triglicerídeo, PAI-1 e IMC. Níveis de PAI-1 foram estatisticamente maiores no grupo controle em indivíduos com genótipo 5G5G, seguido de 4G5G e 4G4G. A Regressão Logística Binária confirmou que as variáveis hipertensão e fibrinogênio foram significantes ao p-valor (0.009) e (0.049) e ODDS Ratio ajustado (4,184; 1,426-12,276) e (3,293; 1,006-10,775) respectivamente, mostrando que hipertensos têm um risco 4,18 vezes maior de terem DM2 insulinizada e que indivíduos com hiperfibrinogenemia possuem um risco 3,29 vezes maior. Com o estudo espera-se contribuir para melhor entendimento das complexas alterações que acompanham o paciente diabético tipo 2 usuário de insulina numa expectativa de buscar adequado tratamento e prevenção para as complicações macrovasculares do diabetes.Texthttp://repositorio.ufes.br/handle/10/5137porUniversidade Federal do Espírito SantoMestrado em Bioquímica e FarmacologiaPrograma de Pós-Graduação em Bioquímica e FarmacologiaUFESBRCentro de Ciências da SaúdeDiabetes Mellitus tipo 2InsulinaHemostasiaInflamaçãoFarmacologia Bioquímica e Molecular61Caracterizações bioquímica e hemostática de pacientes com diabetes Mellitus Tipo 2 em insulinizaçãoinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)instname:Universidade Federal do Espírito Santo (UFES)instacron:UFESORIGINALtese_7214_DISSERTAÇÃO_FINAL_corrigida - Nadmy.pdfapplication/pdf1059919http://repositorio.ufes.br/bitstreams/5a43e0fe-1dd4-4b18-a476-126764bdd8dc/downloadbddf015e3219b09f72d173ed805157faMD5110/51372024-06-27 11:01:30.737oai:repositorio.ufes.br:10/5137http://repositorio.ufes.brRepositório InstitucionalPUBhttp://repositorio.ufes.br/oai/requestopendoar:21082024-06-27T11:01:30Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) - Universidade Federal do Espírito Santo (UFES)false |
dc.title.none.fl_str_mv |
Caracterizações bioquímica e hemostática de pacientes com diabetes Mellitus Tipo 2 em insulinização |
title |
Caracterizações bioquímica e hemostática de pacientes com diabetes Mellitus Tipo 2 em insulinização |
spellingShingle |
Caracterizações bioquímica e hemostática de pacientes com diabetes Mellitus Tipo 2 em insulinização Gonçalves, Nadmy Arrivabene Zavaris Diabetes Mellitus tipo 2 Insulina Hemostasia Inflamação Farmacologia Bioquímica e Molecular 61 |
title_short |
Caracterizações bioquímica e hemostática de pacientes com diabetes Mellitus Tipo 2 em insulinização |
title_full |
Caracterizações bioquímica e hemostática de pacientes com diabetes Mellitus Tipo 2 em insulinização |
title_fullStr |
Caracterizações bioquímica e hemostática de pacientes com diabetes Mellitus Tipo 2 em insulinização |
title_full_unstemmed |
Caracterizações bioquímica e hemostática de pacientes com diabetes Mellitus Tipo 2 em insulinização |
title_sort |
Caracterizações bioquímica e hemostática de pacientes com diabetes Mellitus Tipo 2 em insulinização |
author |
Gonçalves, Nadmy Arrivabene Zavaris |
author_facet |
Gonçalves, Nadmy Arrivabene Zavaris |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
Bem, Daniela Amorim Melgaço Guimarães do |
dc.contributor.author.fl_str_mv |
Gonçalves, Nadmy Arrivabene Zavaris |
dc.contributor.referee1.fl_str_mv |
Vassalo, Breno Valentim |
dc.contributor.referee2.fl_str_mv |
Gomes, Isabele Beserra Santos |
contributor_str_mv |
Bem, Daniela Amorim Melgaço Guimarães do Vassalo, Breno Valentim Gomes, Isabele Beserra Santos |
dc.subject.por.fl_str_mv |
Diabetes Mellitus tipo 2 Insulina Hemostasia Inflamação |
topic |
Diabetes Mellitus tipo 2 Insulina Hemostasia Inflamação Farmacologia Bioquímica e Molecular 61 |
dc.subject.cnpq.fl_str_mv |
Farmacologia Bioquímica e Molecular |
dc.subject.udc.none.fl_str_mv |
61 |
description |
The study aims to characterize biochemically and hemostatic mellitos patients with diabetes mellitus type 2 (DM2) who developed insulin regimen. Composed group under analysis, 40 patients attended the Basic Health Unit of Consolation, Vitória / ES, aged 25 to 80 years, diagnosed with DM2 and that were already evoluted to insulinization. As controls, 40 patients were selected in the same age group without laboratory and / or clinical diagnosis of DM. Markers of inflammation, hypercoagulability and fibrinolysis were measured: Fibrinogen, D-dimer (D-Di) and plasminogen activator type 1 inhibitor (PAI-1). The polymorphism (-675 4G/5G) in the promoter region of the PAI-1 gene was correlated with their serum levels. Biochemical parameters were measured: plasma glucose (PG), glycated hemoglobin (A1C), total cholesterol (TC), HDL cholesterol (HDL-C), LDL (LDLc) cholesterol, triglycerides (TGC), ultrasensitive C reactive protein (hsCRP), urea and serum creatinine. There was still checking BMI, obesity, smoking, hypothyroidism, hypertension, dyslipidemia and insulin resistance. Statistical analysis showed significant differences (p <0.05) between groups with regard to mean values of HDLC, VLDL-C, TGC, urea, hsCRP and fibrinogen. There was significant difference between groups for VLDLc, TGC, creatinine and fibrinogen. Controls present correlations between: fibrinogen and glucose, hsCRP and fibrinogen, PAI-1 and glucose, PAI-1 and BMI. In insulinization DM2 group correlation was observed correlation between: fibrinogen and D-di, hsCRP and fibrinogen, D-Di and glucose (negative), PAI-1 and triglycerides, PAI-1 and BMI. PAI-1 levels were higher in the control group in subjects with genotype 5G5G, 4G5G and 4G4G followed. Binary Logistic Regression confirmed that the variables hypertension and fibrinogen were significant at p-value (0.009) and (0.049) and adjusted odds ratio (4.184, 1.426 to 12.276) and (3.293, 1.006 to 10.775), respectively, showing that hypertensive patients have a risk 4.18 times more likely to have insulinization type 2 diabetes and that individuals with hyperfibrinogenemia have a 3.29 times greater risk. With this study we hope to contribute to better understanding of the complex changes that accompany the user insulinization type 2 diabetic patients in expectation of seeking appropriate treatment and prevention for the macrovascular complications of diabetes. |
publishDate |
2014 |
dc.date.issued.fl_str_mv |
2014-07-15 |
dc.date.accessioned.fl_str_mv |
2016-08-29T15:37:45Z |
dc.date.available.fl_str_mv |
2016-07-11 2016-08-29T15:37:45Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://repositorio.ufes.br/handle/10/5137 |
url |
http://repositorio.ufes.br/handle/10/5137 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
Text |
dc.publisher.none.fl_str_mv |
Universidade Federal do Espírito Santo Mestrado em Bioquímica e Farmacologia |
dc.publisher.program.fl_str_mv |
Programa de Pós-Graduação em Bioquímica e Farmacologia |
dc.publisher.initials.fl_str_mv |
UFES |
dc.publisher.country.fl_str_mv |
BR |
dc.publisher.department.fl_str_mv |
Centro de Ciências da Saúde |
publisher.none.fl_str_mv |
Universidade Federal do Espírito Santo Mestrado em Bioquímica e Farmacologia |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) instname:Universidade Federal do Espírito Santo (UFES) instacron:UFES |
instname_str |
Universidade Federal do Espírito Santo (UFES) |
instacron_str |
UFES |
institution |
UFES |
reponame_str |
Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) |
collection |
Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) |
bitstream.url.fl_str_mv |
http://repositorio.ufes.br/bitstreams/5a43e0fe-1dd4-4b18-a476-126764bdd8dc/download |
bitstream.checksum.fl_str_mv |
bddf015e3219b09f72d173ed805157fa |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 |
repository.name.fl_str_mv |
Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) - Universidade Federal do Espírito Santo (UFES) |
repository.mail.fl_str_mv |
|
_version_ |
1804309171061915648 |